{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:40:52Z","timestamp":1770741652904,"version":"3.49.0"},"reference-count":20,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (GIT 2.0) instrument is a self-report tool measuring gastrointestinal (GI) quality of life in patients with systemic sclerosis (SSc). Scarce data are available on the correlation between patient-reported GI symptoms and motility dysfunction as assessed by esophageal transit scintigraphy (ETS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the GIT 2.0 reflux scale in patients with SSc admitted to our clinic and undergoing ETS, and correlated their findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-one patients with SSc undergoing ETS were included. Twenty-seven were female, and 9 had diffuse cutaneous SSc. Twenty-six of 31 (84%) patients had a delayed transit and an abnormal esophageal emptying activity (EA); they also had a higher GIT 2.0 reflux score (<jats:italic>P<\/jats:italic> = 0.04). Mean EA percentage was higher in patients with none to mild GIT 2.0 reflux score (81.1 [SD 11.5]) than in those with moderate (55.7 [SD 17.8], <jats:italic>P<\/jats:italic> = 0.003) and severe to very severe scores (55.8 [SD 19.7], <jats:italic>P<\/jats:italic> = 0.002). The percentage of esophageal EA negatively correlated with the GIT 2.0 reflux score (r = \u20130.68, <jats:italic>P<\/jats:italic> &lt; 0.0001), but it did not correlate with the other GIT 2.0 scales and the total GIT 2.0 score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SSc patients with impaired ETS findings have a higher GIT 2.0 reflux score. The GIT 2.0 is a complementary tool for objective measurement of esophageal involvement that can be easily administered in day-to-day clinical assessment.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.201283","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:20:42Z","timestamp":1610716842000},"page":"1422-1426","source":"Crossref","is-referenced-by-count":10,"title":["UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-0133","authenticated-orcid":false,"given":"Giuseppina","family":"Abignano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna Angela","family":"Mennillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-554X","authenticated-orcid":false,"given":"Giovanni","family":"Lettieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-2032","authenticated-orcid":false,"given":"Duygu Temiz","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3112-6488","authenticated-orcid":false,"given":"Antonio","family":"Carriero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Anna","family":"Padula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-1110","authenticated-orcid":false,"given":"Salvatore","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2022062114102630000_48.9.1422.1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022062114102630000_48.9.1422.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370902"},{"key":"2022062114102630000_48.9.1422.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110923"},{"key":"2022062114102630000_48.9.1422.4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11938-016-0108-9","article-title":"Gastrointestinal transit assessment: role of scintigraphy: where are we now? Where are we going?","volume":"14","author":"Ziessman","year":"2016","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2022062114102630000_48.9.1422.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180004"},{"key":"2022062114102630000_48.9.1422.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24730"},{"key":"2022062114102630000_48.9.1422.7","first-page":"57","article-title":"Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis","volume":"2","author":"Bae","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114102630000_48.9.1422.8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.semarthrit.2017.05.005","article-title":"High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in systemic sclerosis","volume":"47","author":"Abozaid","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2022062114102630000_48.9.1422.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"2022062114102630000_48.9.1422.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202843"},{"key":"2022062114102630000_48.9.1422.11","first-page":"S55","article-title":"Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis","volume":"33","author":"Gualtierotti","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114102630000_48.9.1422.12","first-page":"112","article-title":"[HAQ-DI Italian version in systemic sclerosis.]","volume":"58","author":"La Montagna","year":"2006","journal-title":"Reumatismo"},{"key":"2022062114102630000_48.9.1422.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401110"},{"key":"2022062114102630000_48.9.1422.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000434668.32150.e5"},{"key":"2022062114102630000_48.9.1422.15","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/acr.20598","article-title":"Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler\u2019s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud\u2019s Condition Score (RCS)","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022062114102630000_48.9.1422.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110225"},{"key":"2022062114102630000_48.9.1422.17","first-page":"S15","article-title":"Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"2","author":"Bae","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114102630000_48.9.1422.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110060"},{"key":"2022062114102630000_48.9.1422.19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/17000205"},{"key":"2022062114102630000_48.9.1422.20","first-page":"297","article-title":"Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method","volume":"23","author":"Kaye","year":"1996","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:18:22Z","timestamp":1655846302000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.3899\/jrheum.201283"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201283","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}